• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Pressure BioSciences, Inc.

    7/16/21 2:44:13 PM ET
    $PBIO
    Get the next $PBIO alert in real time by email
    SC 13G 1 f13g071621_sc13g.htm SCHEDULE 13G Schedule 13G

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

    Pressure BioSciences, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    74112E208

    (CUSIP Number)

     

    July 16, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [   ] Rule 13d-1(b) 

    [X] Rule 13d-1(c) 

    [   ] Rule 13d-1(d) 

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     

     

    CUSIP No. 74112E208

     

    13G

     

    1

    NAMES OF REPORTING PERSONS UNION CAPITAL, LLC

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

     

     

    EAGLE EQUITIES, LLC

     

    35-2553872

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (see instructions)

     

    (a) [   ]

     

    (b) [X]

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

     

     

    NEVADA

     

    NUMBER OF

    SHARES BENEFICIALLY

    OWNED

    BY EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    300,000

     

    6

    SHARED VOTING POWER

     

    0

     

    7

    SOLE DISPOSITIVE POWER

     

    300,000

     

    8

    SHARED DISPOSITIVE POWER

     

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    300,000

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    (see instructions) [   ]

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.20%

     

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     


     

     

    CUSIP No. 74112E208

     

    13G

     

    Item 1.

     

     

    (a)

    Name of Issuer

    Pressure BioSciences, Inc., a Massachusetts corporation

     

     

     

     

    (b)

    14 Norfolk Avenue South Easton, MA 02375

     

    Item 2.

     

     

    (a)

    Name of Person Filing

    Eagle Equities, LLC

     

     

     

     

    (b)

    Address of the Principal Office or, if none, residence

    390 Whalley Ave. New Haven, CT 06511

     

     

     

     

    (c)

    Citizenship

    Nevada LLC

     

     

     

     

    (d)

    Title of Class of Securities

    Common Stock

     

     

     

     

    (e)

    CUSIP Number

    74112E208

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

     

    (a)

    [   ]

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

     

     

     

     

    (b)

    [   ]

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (c)

    [   ]

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (d)

    [   ]

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

     

     

     

     

    (e)

    [   ]

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    (f)

    [   ]

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    [   ]

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

     

     

     

     

    (h)

    [   ]

    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

     

    (i)

    [   ]

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

     

     

     

     

    (j)

    [   ]

    Group, in accordance with §240.13d-1(b)(1)(ii)(J).


     

     

    CUSIP No. 74112E208

     

    13G

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

    (a)

    Amount beneficially owned: 300,000

     

     

     

     

     

    (b)

    Percent of class: 5.20%

     

     

     

     

     

    (c)

    Number of shares as to which the person has:

     

     

     

     

     

     

    (i)

    Sole power to vote or to direct the vote 300,000

     

     

     

     

     

     

    (ii)

    Shared power to vote or to direct the vote

     

     

     

     

     

     

    (iii)

    Sole power to dispose or to direct the disposition of 300,000

     

     

     

     

     

     

    (iv)

    Shared power to dispose or to direct the disposition of

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Item 9. Notice of Dissolution of Group.

     

    Item 10. Certification.

     

     

    (a)

    The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

     

     

     

     

     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

     

    (b)

    The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):

     

     

     

     

     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     


     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    7/16/2021

    Date

     

    /s/ Yakov D Borenstein

    Signature

     

    Member

    Name/Title

     

    Get the next $PBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Peterson Jeffrey N acquired $1,670 worth of shares (59,652 units at $0.03), increasing direct ownership by 72% to 142,084 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:23 PM ET
      $PBIO
    • Director Urdea Michael S acquired $404 worth of shares (14,429 units at $0.03), increasing direct ownership by 44% to 47,588 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:20 PM ET
      $PBIO
    • President, CEO Schumacher Richard T acquired $641 worth of shares (22,878 units at $0.03), increasing direct ownership by 38% to 82,967 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:21 PM ET
      $PBIO

    $PBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc.

      SOUTH EASTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biotherapeutics, and more, is excited to announce promising early financial results from its January 19, 2024 acquisition of Uncle Bud's Health & Wellness ("UB"). Key highlights from Uncle Bud's first month following its acquisition by PBIO include: Amazon Business Rapid Growth: Amazon sales have surged, inc

      2/26/24 9:06:01 AM ET
      $PBIO

    $PBIO
    Financials

    Live finance-specific insights

    See more
    • Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness

      Multi-Patented Nanoemulsification Platform Enables Wide-Range of Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in 2024 Anticipated with Further Acceleration in 2025 & Beyond Pressure BioSciences February 5th Investor Call to Discuss Impact of Recent Uncle Bud's Acquisition SOUTH EASTON, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biothe

      2/5/24 8:23:04 AM ET
      $PBIO
    • Pressure BioSciences, Inc. Reports Q3 2023 Financial Results, Provides Business Update, and Offers Guidance for Remainder of 2023

      Investor Call Scheduled for Tuesday, November 21, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / November 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmeceuticals, agriculture, and food & beverage industries, today reported financial results for the third quarter ended September 30, 2023, provided a business update, and offered limited guidance for expected achievements through the remainder of 2023.Financial Highlights: Q3 2023 vs. Q3 2022 (rounded to nearest

      11/21/23 9:28:00 AM ET
      $PBIO
    • Pressure BioSciences, Inc. to Discuss Third Quarter 2023 Financial Results and Provide Business Update

      Conference Call Scheduled for Tuesday, November 21 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / November 20, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2023 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, November 21, 2023. Time: 4:30 PM Eastern Time (ET).To attend thi

      11/20/23 9:15:00 AM ET
      $PBIO

    $PBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pressure BioSciences, Inc. (Amendment)

      SC 13G/A - PRESSURE BIOSCIENCES INC (0000830656) (Subject)

      7/30/21 2:54:00 PM ET
      $PBIO
    • SEC Form SC 13G filed by Pressure BioSciences, Inc.

      SC 13G - PRESSURE BIOSCIENCES INC (0000830656) (Subject)

      7/16/21 2:44:13 PM ET
      $PBIO

    $PBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET

      CANTON, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Thursday, June 20, 2024 at 4:30pm ET. Topics to be discussed include: FY 2023 financial and business results.FY 2024 financial and business outlook.Status of Company's relocation to its new manufacturing facility.Status of Company's new Joint Venture Program.Update on Uncle Bud's Health and WellnessProduct expansion – expected Q3/Q4 2024 release of new nanoemulsified products, i

      6/18/24 8:16:05 AM ET
      $PBIO
    • Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET

      SOUTH EASTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Wednesday, June 19, 2024 at 4:30 PM ET. The topics to be discussed include but are not limited to: FY 2023 financial and business results.FY 2024 financial and business outlook.Status of Company's relocation to its new manufacturing facility.Update on Uncle Bud's Health and WellnessProduct expansion – expected Q3/Q4 2024 commercial release of new nanoemulsified products: N

      6/13/24 10:13:34 AM ET
      $PBIO
    • Uncle Bud's Health and Wellness to Expand New Premium Collection with Novel Products for Sleep, Memory, Pain, Immunity, Feminine Hygiene, and Sexual Wellness

      SOUTH EASTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today revealed that its wholly-owned Uncle Bud's Health & Wellness direct-to-consumer ("DTC") subsidiary ("Uncle Bud's") has announced an expansion of products and categories in 2024 to its recently formed "Premium Collection" of state-of-the-art nanoemulsified products. Premium Collection products

      4/11/24 10:52:23 AM ET
      $PBIO

    $PBIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pressure BioSciences, Inc.

      10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      2/7/25 5:30:43 PM ET
      $PBIO
    • SEC Form 10-Q filed by Pressure BioSciences, Inc.

      10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      9/6/24 5:17:19 PM ET
      $PBIO
    • SEC Form NT 10-Q filed by Pressure BioSciences, Inc.

      NT 10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      8/19/24 5:20:09 PM ET
      $PBIO